What ONCare
Is Building

ONCARE ALLIANCE — FIERCELY INDEPENDENT, BY DESIGN

Independent practice does not have to die. ONCare is building a nationwide network of independent oncologists — and then, on the same playbook, networks of the other independent specialists that consolidation has squeezed. Physician-led and opt-in — the opposite of the roll-up that takes more than half the money off the top before a dollar reaches patient care. None of this is a simple path. But it is a navigable one, taken smartly and together.

WHY NOW

The economics that have kept independent specialty practice alive are being pulled out from under independent practice — all at once. That is precisely why the moment to build the alternative is now, while independent physicians still set the terms.

The drug margin is collapsing

The economics that sustained independent oncology are eroding under the IRA. Independent practices are the most exposed — and the least able to absorb it.

The cuts are landing

Medicaid reductions and renewed pressure on the Part B fee schedule pull money out of a system that was never built to give it back without consequence.

Consolidation holds the gun

The large systems set the terms in too many markets. The way out is not to bargain harder — it is to build an aligned path with the plans directly.

The window is open now — and it is the independents who should walk through it first.

THE MODEL, IN PLAIN TERMS

A payment model that rewards the care that keeps patients well — built so a plan can switch it on, not build it from scratch.

Off the drug margin

Money moves off the drug margin and into transparent payment for the work that actually keeps patients out of the hospital: treatment planning, care coordination, and nurse-navigator triage.

On rails they already run

Settled on facility fees and episode categories that look like the ambulatory payment categories Medicare already uses, and on Solventum’s Clinical Risk Groups the plans already license. Start small, prove it, then scale.

You share in the savings

You grow revenue, the per-member payment is protected, and you share in the savings created when your patients stay out of the hospital and the ED — savings that today land where you never see them. An independent calculation protects that share, so control never shifts to the plan.

It has a track record. An earlier version of this design was recommended 7–0 by Medicare’s own technical advisory panel (PTAC, 2018), and ASCO formally backed the current model in 2026. This is not theory — it is a model the field has already vetted.

HOW THE NETWORK GROWS

Patients receiving care under the model

PROVING GROUND · TODAY

NMOHC

A proven independent oncology practice — the COME HOME heritage that keeps patients out of the hospital and the ED, and shows the model works on real patients.

NEAR-TERM · BUILDING

New Mexico Independent Doctors

Barbara’s separate New Mexico vehicle — a first-of-its-kind multi-specialty network, alongside the ONCare oncology alliance, not part of it. Not built on a hospital or on primary care. It controls specialty access in its market, so the plans that contract get priority — shifting the balance of power. One contract; kidney care the start-small demonstration.

OncologyGIRenal GYN-OncOphthalmologyDermatology ASC

THE VISION · NATIONAL

ONCare Alliance

A nationwide network of independent oncologists — then, on the same playbook, the other independent specialists consolidation has squeezed, on infrastructure the plans already hold.

It is all specialties. Oncology is the proving ground, not the ceiling. The model is built to carry GI, kidney care, rheumatology, and the specialties that follow.

WHAT ONCARE NAVIGATES — TOGETHER

An honest account of the obstacles — and how each one gets cleared without putting the burden on your practice.

THE SPEEDBUMPS

A large plan moves carefully. Security and privacy review is rigorous — no payor wants to be the next headline breach.
Much of a plan’s oncology already runs through an incumbent vendor (at HCSC, Carelon). Anything new has to fit around what is already in place.
At Enterprise scale there is little appetite for custom builds — a proposal has to run on systems the plan already operates.
The macro pressure is real and arriving at once: Medicaid cuts, Part B pressure, and the drug-margin squeeze.

HOW EACH ONE CLEARS, TOGETHER

The plan builds nothing — it simply turns on what it already licenses; Solventum’s CRGs are already contracted in.
The work runs on the plan’s own claims, in the plan’s own environment; the data never leaves its house.
The cleanest on-ramp funds a practice already in-network to stand the work up — so nothing waits on a multi-year security review, and no new vendor takes the plan’s data.
One plan goes first as the pioneer, proves it small, then carries it to the next.
The measurement partner sits alongside, paid by the plan — so your practice takes on no new cost and no new IT lift.

THE THESIS, IN ONE LINE

Independent physicians deliver the outcomes. ONCare builds the network — and the payment that finally rewards it — on infrastructure the plans already hold.

WHO THIS IS FOR

Independent practices that intend to stay independent. Oncology first — then GI, kidney care, GYN-oncology, ophthalmology, dermatology, ambulatory surgery, and the other specialists consolidation has squeezed. If you lead one, there is a seat in this.

NEXT STEP

For now, the conversation runs through Barbara McAneny, MD; an oversight group helps lead the work, and where this is headed is a nationwide network. If you lead an independent practice and want in, start the conversation.